Skip to main content

Advertisement

SpringerLink
Log in

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases

  • Case Report
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2–14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Goff BA, Sainz de la Cuesta R, Muntz HG et al (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60:412–417

    Article  PubMed  CAS  Google Scholar 

  2. Recio FO, Piver MS, Hempling RE et al (1996) Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78:2157–2163

    Article  PubMed  CAS  Google Scholar 

  3. Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88:2584–2589

    Article  PubMed  CAS  Google Scholar 

  4. Pectasides D, Fountzilas G, Aravantinos G et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285–291

    Article  PubMed  Google Scholar 

  5. Enomoto T, Kuragaki C, Yamasaki M et al (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22:abstr 1797

    Google Scholar 

  6. Ho CM, Huang YJ, Chen TC et al (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94:197–203

    Article  PubMed  CAS  Google Scholar 

  7. Takano M, Sugiyama T, Yaegashi N et al (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18:937–942

    Article  PubMed  CAS  Google Scholar 

  8. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  PubMed  CAS  Google Scholar 

  9. Bellmunt J, Szczylik C, Feingold J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387–1392

    Article  PubMed  CAS  Google Scholar 

  10. Malizzia LJ, Hsu A (2008) Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 12:639–646

    Article  PubMed  Google Scholar 

  11. Lee S, Garner EI, Welch WR et al (2007) Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106:311–317

    Article  PubMed  CAS  Google Scholar 

  12. Miyazawa M, Yasuda M, Fujita M et al (2009) Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59:19–27

    Article  PubMed  CAS  Google Scholar 

  13. Mabuchi S, Kawase C, Altomare DA et al (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15:5404–5413

    Article  PubMed  CAS  Google Scholar 

  14. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21(10 Suppl):187s–193s

    Article  PubMed  Google Scholar 

  15. Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374

    Article  PubMed  CAS  Google Scholar 

  16. Kuo KT, Guan B, Feng Y et al (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036–4042

    Article  PubMed  CAS  Google Scholar 

  17. Osada R, Horiuchi A, Kikuchi N et al (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310–1320

    Article  PubMed  CAS  Google Scholar 

  18. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253–262

    Article  PubMed  CAS  Google Scholar 

  19. Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014

    Article  PubMed  CAS  Google Scholar 

  20. Harding MW (2003) Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 9:2882–2886

    PubMed  CAS  Google Scholar 

  21. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549–5554

    Article  PubMed  CAS  Google Scholar 

  22. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347

    Article  PubMed  CAS  Google Scholar 

  23. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918

    Article  PubMed  CAS  Google Scholar 

  24. Crotzer DR, Sun CC, Coleman RL et al (2007) Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105:404–408

    Article  PubMed  Google Scholar 

  25. Utsunomiya H, Akahira J, Tanno S et al (2006) Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52–56

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

    Masashi Takano, Tomoko Goto & Kenichi Furuya

  2. Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, 359-1133, Japan

    Yoshihiro Kikuchi

  3. Department of Obstetrics and Gynecology, Nishisaitama-chuo National Hospital, Tokorozawa, Saitama, 359-1151, Japan

    Kazuya Kudoh

  4. Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan

    Ryoko Kikuchi

  5. Department of Obstetrics and Gynecology, Nara Prefectural Nara Hospital, Nara, Nara, 631-0846, Japan

    Tsunekazu Kita

  6. Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, 350-1298, Japan

    Keiichi Fujiwara

  7. Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan

    Tanri Shiozawa

  8. Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan

    Daisuke Aoki

Authors
  1. Masashi Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuya Kudoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryoko Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tsunekazu Kita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keiichi Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tanri Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daisuke Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masashi Takano.

About this article

Cite this article

Takano, M., Kikuchi, Y., Kudoh, K. et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases . Int J Clin Oncol 16, 605–609 (2011). https://doi.org/10.1007/s10147-010-0177-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-010-0177-z

Keywords

Search

Navigation